GlassScriptPhysician profile
Julian Mclain
NPI 1063916591
$8,980.44
in general payments reported to CMS, 2019-2025
48 companies · $2,670 in 2025
The $2,670 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.99 · 2021: $930 · 2022: $1,900 · 2023: $2,032 · 2024: $1,426 · 2025: $2,670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,045 · Education: $82.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,045.27 |
| Education | $82.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $1,043.44 | 2021-2025 | Pomalyst, Opdivo, Reblozyl |
| Genzyme Corporation | $942.82 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $791.04 | 2021-2025 | Enhertu, Calquence, Tagrisso |
| Seagen INC. | $712.86 | 2021-2023 | Adcetris, Tukysa |
| Abbvie INC. | $493.56 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $483.03 | 2021-2025 | Zepzelca, Rylaze |
| Incyte Corporation | $479.94 | 2020-2025 | Monjuvi, Jakafi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $343.99 | 2022-2025 | Opdivo, Pomalyst, Opdualag |
| Janssen Biotech, INC. | $297.27 | 2024-2025 | Tecvayli, Erleada, Balversa |
| Amgen INC. | $286.20 | 2021-2023 | Kyprolis |
| Novartis Pharmaceuticals Corporation | $284.72 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $273.03 | 2022-2025 | Keytruda, Lynparza, Prevymis |
| Emd Serono, INC. | $173.88 | 2023-2024 | Bavencio |
| Karyopharm Therapeutics INC. | $152.62 | 2021-2023 | Xpovio |
| Ipsen Biopharmaceuticals, INC | $151.59 | 2022-2024 | Somatuline Depot, Onivyde |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $130.15 | 2023-2025 | Enhertu, Datroway |
| Agios Pharmaceuticals, INC. | $128.91 | 2024-2025 | Pyrukynd |
| Gilead Sciences, INC. | $126.54 | 2022-2025 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $124.83 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.84 | 2021-2025 | Fruzaqla, Alunbrig, Livtencity |
| Blueprint Medicines Corporation | $118.41 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $109.35 | 2022-2025 | Libtayo |
| Astellas Pharma US INC | $99.03 | 2025 | Xtandi, Vyloy |
| Puma Biotechnology, INC. | $83.30 | 2023-2025 | Nerlynx |
| Glaxosmithkline, LLC. | $77.52 | 2024-2025 | Ojjaara, Blenrep |
| Adc Therapeutics America, INC. | $73.81 | 2025 | |
| Servier Pharmaceuticals LLC | $71.30 | 2023-2024 | |
| Kite Pharma, INC. | $66.00 | 2025 | Yescarta |
| Novocure INC. | $65.12 | 2025 | Optune Lua (Novottf-200t), Optune Gio |
| Tempus Ai, INC | $64.45 | 2025 | Xt Cdx |
| Lilly USA, LLC | $54.13 | 2024-2025 | Verzenio |
| Pfizer INC. | $52.54 | 2025 | |
| Eisai INC. | $47.89 | 2022-2024 | |
| Rigel Pharmaceuticals, INC. | $47.23 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Taiho Oncology, INC. | $45.45 | 2025 | |
| Beigene USA, INC. | $43.36 | 2024 | Brukinsa |
| Deciphera Pharmaceuticals INC. | $42.53 | 2023 | Qinlock |
| Beone Medicines USA, INC. | $30.21 | 2025 | Brukinsa |
| Array Biopharma INC | $29.94 | 2025 | Lorbrena, Xalkori, Braftovi |
| Adaptive Biotechnologies Corporation | $29.75 | 2025 | Clonoseq |
| Geron Corporation | $27.84 | 2025 | Rytelo |
| Coherus Oncology, INC. | $26.88 | 2024 | |
| Exelixis INC. | $24.11 | 2024 | Cabometyx |
| Genentech USA, INC. | $23.33 | 2024 | Phesgo, Alecensa |
| Aveo Pharmaceuticals, INC. | $22.70 | 2023 | Fotivda |
| Bayer Healthcare Pharmaceuticals INC. | $21.77 | 2025 | |
| Aadi Bioscience, INC. | $21.38 | 2025 | Fyarro |
| Caris Mpi, INC. | $20.85 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julian Mclain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.